Families frequently express concern about blood pressure control in our patient population. This study supports the idea that low blood pressure may be assoicated with symptoms related to hypotension in patients over the age of 80. Still, elevated BP is associated with increased risk of CVA
TITLE
Is Blood Pressure Lowering in the Very Elderly With Previous Stroke Associated With a Higher Risk of Adverse Events?
JOURNAL
Journal of the American Heart Association
DOI
10.1161/JAHA.121.022240
Author(s)
D Tharmaratnam;CC Karayiannis;TA Collyer;H Arima;LA McClure;J Chalmers;CS Anderson;OR Benavente;CL White;A Algra;C Moran;TG Phan;WC Wang;V Srikanth;
Abstract
Background: We investigated whether blood pressure lowering for secondary prevention is associated with a reduction in recurrent stroke risk and/or a higher risk of adverse events in very elderly compared with younger trial participants. Conclusions: Very elderly people in secondary prevention trials of blood pressure lowering have an increased risk of hypotensive symptoms, but with no statistical increase in the risk of falls, syncope, or mortality. However, evidence is lacking for frail elderly with multiple comorbidities who may be more vulnerable to adverse effects of blood pressure lowering.
Shingles is a painful rash caused by the same virus that causes chicken pox in youth: herpes zoster. The zoster vaccine is effective in preventing shingles and is recommended for patients over 50. This study indicates that the benfit of the zoster vaccine is present even 10 years after the vaccination is given.
TITLE
Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
JOURNAL
The Journal of infectious diseases
DOI
10.1093/infdis/jiaa300
Author(s)
A Hastie;G Catteau;A Enemuo;T Mrkvan;B Salaun;S Volpe;J Smetana;L Rombo;T Schwarz;K Pauksens;C Hervé;A Bastidas;A Schuind
Abstract
BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV) is highly immunogenic and efficacious in adults ≥50 years of age. We evaluated (1) long-term immunogenicity of an initial 2-dose RZV schedule, by following up adults vaccinated at ≥60 years of age and by modeling, and (2) immunogenicity of 2 additional doses administered 10 years after initial vaccination.
CONCLUSIONS: Immune responses to an initial 2-dose RZV course persisted for many years in older adults. Strong anamnestic immune responses can be induced by additional dosing 10 years after the initial 2-dose course. CLINICAL TRIALS REGISTRATION NCT02735915.
